Using Behavioral AI to Predict and Prevent Clinical Trial Dropouts
At SCOPE Europe 2025, we spoke with Dominique Demolle, CEO of Cognivia, about how behavioral AI is helping sponsors...
Moe Alsumidaie
Veeva and OpenEvidence Form Strategic AI Partnership to Revolutionize Trial Access and Therapeutic Adoption
In a strategic move that signals a broader shift toward embedded AI in clinical workflows, Veeva Systems and OpenEvidence...
Risk-Based Oversight Redefined: How E6R3 is Reshaping Vendor Governance
At the SCOPE Europe 2025 conference, industry experts underscored how ICH E6(R3) is transforming the way sponsors approach vendor...
Imaging as Infrastructure: Why Sponsors Must Rethink Oversight in Modern Trials
At DPHARM, we spoke with Paul McCracken, founder and principal of RadiaNova Consulting, about the overlooked pitfalls in clinical...
Exosome Exotherapy: Lior Shaltiel on a Platform for CNS Regeneration
Today, we sit down with Dr. Lior Shaltiel of NurExone Biologics to explore how exosome-based delivery of siRNA could...
First Pharma to Restore Sense of Smell? Inside the FLAVOR Trial Quest to Treat Postviral Olfactory Loss
In this interview, I’m talking with Rick Geoffrion, Founder, President, and CEO of Cyrano Therapeutics, about FLAVOR, a Phase...
“Minutes, Not Days”: Site-Centric AI and Clinical Trial Experience
The coordinator stared at a 400-page EHR export, convinced the week was lost—until an AI pre-screen flagged 23 likely-eligible...
How Small Biotechs Navigate Clinical Trial Vendor Oversight
At SCOPE Europe 2025, a panel on vendor identification, selection, and management highlighted a pragmatic blueprint for small biopharma:...
Shining Light on Women’s Health: A New Non-Drug Vaginal Therapy
In this interview, I spoke with Dr. Melanie Santos, Chief Medical Officer at Cern Corporation, about a novel low...
The Human Cost of Fragmented Technology: A Conversation with Veeva’s Bree Burks
At the Veeva R&D and Quality Summit in Boston, we spoke with Bree Burks, Vice President of Strategy at...